STAMFORD, Conn., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that new preclinical data for the company’s LOXO-292 and LOXO-195 programs will be presented at the 28 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 – December 2, 2016 in Munich, Germany.
The details of the poster presentations are as follows:
LOXO-292
Date : December 1, 2016 Title : The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers Session : Molecular targeted agents II Abstract Code : 441 Poster Number : 120 Location : Exhibition Hall
LOXO-195
Date : December 1, 2016 Title : The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers Session : Molecular targeted agents II Abstract Code : 442 Poster Number : 121 Location : Exhibition Hall
About Loxo Oncology Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com .
Contacts for Loxo Oncology, Inc.
Company: Jacob S. Van Naarden Chief Business Officer jake@loxooncology.com
Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com
Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com
